Published in Chest on December 01, 2005
The difference in clinical presentations between healthcare-associated and community-acquired pneumonia in university-affiliated hospital in Korea. Yonsei Med J (2011) 0.77
Health care-associated Staphylococcus aureus pneumonia. Can J Infect Dis Med Microbiol (2007) 0.76
Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia. Korean J Intern Med (2016) 0.75
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20
A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis (2013) 2.30
Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med (2003) 2.20
Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med (2014) 2.18
Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia? Chest (2013) 2.15
Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest (2006) 1.84
Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis (2009) 1.80
Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med (2014) 1.77
Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest (2007) 1.77
Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit Care Med (2005) 1.71
Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med (2004) 1.61
Hyponatremia in community-acquired pneumonia. Am J Nephrol (2007) 1.59
Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med (2013) 1.48
Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med (2002) 1.27
Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest (2002) 1.27
Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis (2009) 1.21
Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol (2007) 1.16
Who should receive antibiotics for exacerbations of chronic bronchitis? A plea for more outcome-based studies. Clin Infect Dis (2004) 1.10
Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med (2013) 1.09
Community-acquired pneumonia: an unfinished battle. Med Clin North Am (2011) 1.09
Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit. Clin Infect Dis (2008) 1.06
Repeated exposure to low-dose diesel exhaust after allergen challenge exaggerates asthmatic responses in mice. Clin Immunol (2006) 1.01
Diagnosis and treatment of rhinovirus respiratory infections. Chest (2003) 1.00
Newly designed primer sets available for evaluating various cytokines and iNOS mRNA expression in guinea pig lung tissues by RT-PCR. Exp Anim (2005) 1.00
Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis (2010) 0.98
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother (2004) 0.97
Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. Chest (2008) 0.96
The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med (2007) 0.94
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest (2005) 0.93
Nosocomial pneumonia: lessons learned. Crit Care Clin (2013) 0.91
Pulmonary infections and resistance to antibiotics: recent information. Expert Rev Anti Infect Ther (2012) 0.91
Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest (2002) 0.90
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis (2005) 0.87
Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology (2013) 0.87
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents (2013) 0.85
Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia. Crit Care Med (2003) 0.85
Assessment of risk factors for multi-drug resistant organisms to guide empiric antibiotic selection in long term care: a dilemma. J Am Med Dir Assoc (2010) 0.84
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med (2004) 0.83
Clinical issues and research in respiratory failure from severe acute respiratory syndrome. Am J Respir Crit Care Med (2004) 0.83
Year in review 2013: Critical Care--respiratory infections. Crit Care (2014) 0.83
What is the natural history of resolution of nosocomial pneumonia? Semin Respir Crit Care Med (2002) 0.82
Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am (2012) 0.81
Nosocomial pneumonia. Curr Opin Infect Dis (2002) 0.80
Pneumonia complicating pregnancy. Clin Chest Med (2010) 0.80
Viral community-acquired pneumonia: if we do not diagnose it and do not treat it, can it still hurt us? Chest (2010) 0.80
[Clinicopathological analysis of patients with idiopathic pulmonary fibrosis which became acutely exacerbated after video-assisted thoracoscopic surgical lung biopsy]. Nihon Kokyuki Gakkai Zasshi (2002) 0.80
High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res (2003) 0.80
How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med (2002) 0.79
Standardized care for nosocomial pneumonia is a valuable tool to improve patient outcomes: how do we get intensivists to listen? Crit Care Med (2009) 0.78
Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new 'speed limit'? Thorax (2010) 0.78
Understanding the natural history of community-acquired pneumonia resolution: vital information for optimizing duration of therapy. Clin Infect Dis (2004) 0.78
[Evaluation of hepatitis B virus genotyping EIA kit]. Rinsho Byori (2009) 0.78
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest (2002) 0.77
Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. Respirology (2014) 0.77
What is next in sepsis: current trials in sepsis. Expert Rev Anti Infect Ther (2012) 0.77
Improving outcomes in community-acquired pneumonia. Curr Opin Pulm Med (2016) 0.77
Treatment of hospital-acquired pneumonia. Lancet Infect Dis (2011) 0.77
Granulocyte colony-stimulating factor for severe pneumonia: what do we do when the best laid plans for men (and mice and rats...) fail? Crit Care Med (2003) 0.77
Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis (2010) 0.76
Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am (2004) 0.76
Therapy of ventilator-associated pneumonia: what more can we do to use less antibiotics? Crit Care Med (2004) 0.76
Road ahead to respiratory health: experts chart future research directions. Respirology (2009) 0.76
Update in respiratory infections 2011. Am J Respir Crit Care Med (2012) 0.76
Why is Acinetobacter baumannii a problem for critically ill patients? Intensive Care Med (2015) 0.76
Managing ventilator complications in a "VACuum" of data. Chest (2015) 0.75
Distinguishing chemical pneumonitis from bacterial aspiration: still a clinical determination. Crit Care Med (2011) 0.75
How do we achieve adequate therapy for severe infection? Crit Care Med (2003) 0.75
Ventilator-associated pneumonia prevention: response to Silvestri et al. Intensive Care Med (2015) 0.75
Response. Chest (2014) 0.75
Year in review 2012: Critical Care--respiratory infections. Crit Care (2013) 0.75
Does the presence of antibodies justify the use of antibiotics in exacerbations of chronic bronchitis? Am J Respir Crit Care Med (2004) 0.75
Fighting vampires and ventilator-associated pneumonia: is silver the magic bullet? Chest (2010) 0.75
What is the prognosis for using the pneumonia severity index to make site-of-care decisions in community-acquired pneumonia? Chest (2003) 0.75
The Barcelona Declaration from the World Alliance against Antibiotic Resistance: engagement of intensivists. Crit Care (2012) 0.75
The road forward in the management of Acinetobacter infections in the ICU. Intensive Care Med (2015) 0.75
Acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med (2002) 0.75
Can one plus one ever equal three in the antibiotic therapy of sepsis? Crit Care Med (2010) 0.75
Preparing for the unexpected: lessons learned about respiratory infection from the Japanese tsunami of 2011. Chest (2013) 0.75
[Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay]. Rinsho Byori (2007) 0.75
Year in review 2010: tuberculosis, pleural diseases, respiratory infections. Respirology (2011) 0.75
[Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia]. Nihon Kokyuki Gakkai Zasshi (2005) 0.75
[Clinical evaluation of a novel HBsAg quantitative assay]. Rinsho Byori (2007) 0.75
Community-Acquired Pneumonia. Ann Intern Med (2015) 0.75
Respiratory tract infections in community and healthcare settings: epidemiological, diagnostic and management challenges. Curr Opin Pulm Med (2015) 0.75
Pneumonia severity index Class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. 2007. Chest (2009) 0.75
[Fundamental and clinical evaluation of hepatitis B virus core-related antigen assay by LUMIPULSE f]. Rinsho Byori (2006) 0.75
[Conservative use of antibiotics is important, but: "Resistance hysteria is exaggerated"]. MMW Fortschr Med (2003) 0.75
Respiratory tract infections: advances in diagnosis, management and prevention. Clin Chest Med (2011) 0.75